Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083174 · ClinicalTrials.gov registry record · Phase 3
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,560
- Enrollment target
NCT00083174 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 4,560 participants.
The verdict
NCT00083174, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,560 participants
- Enrollment target
Study Summary
RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen. PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.
Interventions
- DRUG exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,560 participants |
| Start Date | 2004-12-03 |
| Est. Completion | 2018-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083174
The ClinicalTrials.gov registry entry for NCT00083174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which exemestane is the first listed.
NCT00083174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083174 about?
NCT00083174 is a clinical study titled "Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer". RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen. PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to c...
What is the current status of trial NCT00083174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,560 participants. The study started on 2004-12-03. Estimated completion is 2018-01-22.
What interventions are being tested in trial NCT00083174?
The interventions under investigation include: exemestane (DRUG).
Who is sponsoring clinical trial NCT00083174?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.